Eli Lilly shares surged 3.58% to close at $1,078.52, driven by strong investor optimism surrounding the company's leading GLP-1 obesity drug portfolio following recent positive FDA developments and clinical announcements.

  • Wall Street consensus targets $1,116.33 for the next 12 months, with forecasts projecting $1,251.50 by end-2026.
  • The stock's momentum builds on a 42.3% gain over the past year, though it currently trades at a high valuation compared to industry averages.
  • This bullish outlook assumes continued revenue growth, projected to reach $62.50 billion by the end of 2026.